IDEC-C2B8: Began a Phase II trial

IDEC Pharmaceuticals Corp. (IDPH), San Diego, Calif. Product: IDEC-C2B8 pan B antibody targeted to the CD20 marker on B cells. Indication: Relapsed, low-grade B-cell lymphoma Status: Began a Phase I...